Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.21037/tlcr.2017.07.05 http://scihub22266oqcxt.onion/10.21037/tlcr.2017.07.05 C5583068!5583068!28904885     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Transl+Lung+Cancer+Res 2017 ; 6 (4): 409-17 Nephropedia Template TP {{tp|p=28904885|t=2017. The clinical utility of circulating tumour cells in patients with small cell lung cancer |pdf=|usr=}}{{28904885}} gab.com Text The clinical utility of circulating tumour cells in patients with small cell lung cancer JO: Transl Lung Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=28904885 #FOAvip Small cell lung cancer (SCLC) accounts for 15% of lung cancer diagnosed worldwide. It is aggressive and characterised by early metastatic spread with rapid development of chemo resistance such that less than 5% of patients diagnosed survive 5 years. Surgery is rarely performed and failure to identify new effective treatments has been attributed in a large part to lack of good quality tumour biopsies available for translational research. Liquid biopsies provide a minimally invasive alternative to traditional tumour biopsy. Circulating tumour cells (CTCs) are abundant in SCLC and can be enriched and isolated from a venous blood sample. In recent years progress has been made into the molecular characterisation of CTCs and their use to form tumour xenografts in mice for preclinical studies. This review will discuss the current status of the clinical utility of CTCs in patients with SCLC, highlighting their potential application to treatment decision making, drug development in clinical trials and preclinical testing. Twit Text FOAVip The clinical utility of circulating tumour cells in patients with small cell lung cancer ????Transl Lung Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=28904885 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28904885 #FOAvip English Wikipedia <ref>{{Cite pmid|28904885}}</ref> The clinical utility of circulating tumour cells in patients with small cell lung cancer #MMPMID28904885 Foy V; Fernandez-Gutierrez F; Faivre-Finn C; Dive C; Blackhall F Transl Lung Cancer Res 2017[Aug]; 6 (4): 409-17 PMID28904885show ga Small cell lung cancer (SCLC) accounts for 15% of lung cancer diagnosed worldwide. It is aggressive and characterised by early metastatic spread with rapid development of chemo resistance such that less than 5% of patients diagnosed survive 5 years. Surgery is rarely performed and failure to identify new effective treatments has been attributed in a large part to lack of good quality tumour biopsies available for translational research. Liquid biopsies provide a minimally invasive alternative to traditional tumour biopsy. Circulating tumour cells (CTCs) are abundant in SCLC and can be enriched and isolated from a venous blood sample. In recent years progress has been made into the molecular characterisation of CTCs and their use to form tumour xenografts in mice for preclinical studies. This review will discuss the current status of the clinical utility of CTCs in patients with SCLC, highlighting their potential application to treatment decision making, drug development in clinical trials and preclinical testing. äThe clinical utility of circulating tumour cells in patients with smal(epmc).pdf DeepDyve Pubget Overpricing